VXRT News and Press, Vaxart Inc. From 07/20/22

Vaxart ( NASDAQ: VXRT ) on Wednesday reported additional phase 1 data showing that its Spike/Nucleocapsid (S+N) oral tablet COVID-19 vaccine induced long-lasting mucosal IgA antibodies against COVID-19, and all tested coronaviruses. This additional data supports i...

Vaccine-induced mucosal IgA antibody responses persisted for up to 1 year and had a higher neutralizing activity compared with convalescent samples Vaxart will leverage data gained from trial as it develops additional vaccine candidates SOUTH SAN FRANCISCO, Calif., July 20, ...

SOUTH SAN FRANCISCO, Calif., July 14, 2022 (GLOBE NEWSWIRE) --  Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, SVP and Chief Scientific Officer, and Dr. Rebecca Flitter, Senior Scientist, each will present data from the company’s COVID-19 oral tablet vaccine d...

Vaxart's ( NASDAQ: VXRT ) board of directors has decided to extend a vote on increasing the number of common shares to garner more votes. At a Jul 6 shareholder meeting, votes cast to that point on the measure were 81% in favor representing 48.5% of all outstanding sha...

Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week. The newsletter keeps you informed of the biggest stories set to make headlines, including upcoming IPOs, investor days, earnings reports and conference presentat...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due t...

Oramed Pharmaceuticals' ( NASDAQ: ORMP ) Thursday announcement it will report Q1 data on its oral COVID-19 vaccine this quarter has boosted its shares as well as that of MyMD Pharmaceuticals ( NASDAQ: MYMD ). MyMD ( MYMD ) partially owns Oravax Medical, a s...

A services agreement that Vaxart recently brokered with contract research organization hVIVO Services Ltd. "may be integral to its Covid vaccine candidate program," according to an SEC filing . That agreement , signed in late June, has hVIVO conducting a characterization s...

Key Proposal #2 has received significant support, but additional votes are needed for approval Leading Independent Proxy Advisory Firms, ISS and Glass Lewis, Support Proposal #2 SOUTH SAN FRANCISCO, Calif., July 01, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasda...

Vaxart ( VXRT ) said on Thursday it had entered an agreement with hVIVO Services Limited, a subsidiary of London-based firm Open Orphan. Under the agreement, hVIVO will conduct a study and develop a human challenge model based on the Omicron variant of SARS-CoV-2 with...